Diagnostics Solutions Strategic Priorities slide image

Diagnostics Solutions Strategic Priorities

Integrated oncology decision support AI-enabled digital solutions for informed, efficient patient management Roche NAVIFYⓇ Digital Pathology PD-L1 Algorithm Interpretation of biomarker NAVIFYⓇ Mutation Profiler Therapy options & clinical trials NAVIFYⓇ Tumor Board Radiology, pathology & clinical data together Flatiron and Foundation Medicine Access to clinico- genomics database Quick, accurate answers for patients Clinically significant variants and combinations - Tier I & II (2) variant EGFR p.L858R VAF 39% RD 7,478 Therapies approved/guidelines-recommended in: Non-small cell lung carci ° afatinib bevacizumab + erlotinib ⚫dacomitinib erlotinib + ramucirumab gefitinib ⚫osimertinib variant TP53 p.P72R VAF 100% RD 2711 no approved therapies 53 SURGINGATIMENTS Confident decisions & standardized care 67
View entire presentation